in the absence of a submission from the holder of the marketing authorisation:
belzutifan (Welireg®) is not recommended for use within NHSScotland.
Indication under review: treatment of adult patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with a programmed death receptor-1 (PD-1) / programmed death ligand (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice298KB (PDF)
Medicine details
- Medicine name:
- belzutifan (Welireg®)
- SMC ID:
- SMC2864
- Indication:
Treatment of adult patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with a programmed death receptor-1 (PD-1) / programmed death ligand (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- Submission type
- Non submission
- Date advice published
- 08 September 2025